2nd Mar 2007 15:56
Deltex Medical Group PLC02 March 2007 Deltex Medical Group plc Details of demonstration of new prototype SupraQ(TM) monitor 19 February 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),the UK's leading haemodynamic monitoring company, confirms details of a publicmeeting where it will demonstrate the latest prototype of the entirelynon-invasive SupraQ haemodynamic monitor. The meeting will take place at 12 noon on Tuesday 6 March in the SouthamptonSuite of the Radisson Edwardian Grafton Hotel at 130 Tottenham Court Road. TheHotel is very close to Warren Street underground and University College LondonHospital. The meeting will start promptly at 12.00: 1. Introduction Ewan Phillips, Finance Director 2. Technology development Dr Graham Lowe, Head of R&D, Deltex Medical 3. Demonstration Mark Blunden & Ellie Philpot, Deltex Medical 4. Suprasternal Doppler - a clinical Professor Mervyn Singer, Intensive Care perspective Unit, University College London Hospital 5. Global market view Dr Graham Lowe 6. Discussion and questions Ewan Phillips There will also be a short presentation on the developments in the USA announcedon 27 February from Deltex Medical's Chief Executive, Andy Hill, at the end ofthe meeting and attendees will have the opportunity to have their ownhaemodynamic status measured with the SupraQ. Plesae register your intention to attend with the Company's company secretary,Paul Mitchell, by sending an email to [email protected]. For further information, please contact:- Deltex Medical Group plc 01243 774 837Ewan Phillips, Finance Director [email protected] Mitchell, Company Secretary [email protected] Gavin Anderson & Company 0207 554 1400Deborah Walter [email protected] Speed [email protected] Charles Stanley Securities 0207 149 6457Russell Cook [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical